High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
With respect to the clinical advantages known for bath PUVA therapy, it was of interest to compare the plasma levels of 8-methoxypsoralen (8-MOP) in bath therapy with those after oral administration for a better insight into the pharmacokinetics of 8-MOP following different modes of application. Considerable high plasma levels of 8-MOP were observed after bath therapy with interindividual variability. The half-life of plasma 8-MOP was markedly shorter after bath PUVA than after oral application. The pharmacokinetic profile of 8-MOP differs according to the mode of application.
Kappes
U P
UP
Department of Dermatology, Friedrich Schiller University, Jena, Germany.
Barta
U
U
Merkel
U
U
Balogh
A
A
Elsner
P
P
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D001494:Baths; D001682:Biological Availability; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D008875:Middle Aged; D011701:PUVA Therapy; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D012869:Skin Absorption; D012871:Skin Diseases / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors; D014867:Water
D017319:Photosensitizing Agents; D014867:Water; D008730:Methoxsalen